Medtech

The Medtech 100 listings reveal an industry reshaping around core offerings, adapting to remote health care and embracing artificial intelligence.


View Rankings

Outlook 2024: Shaping A Medtech Environment Where Technology Leads The Way

 
• By Ashley Yeo

Environmental demands, the evolution of care models, new delivery technologies and AI tools are influencing how medtechs must approach innovation.

Global Medtech Recovers Core Growth After A Year Like No Other

 
• By Ashley Yeo

With many medtechs restructuring for core growth in the post-pandemic era, Abbott relied on organic growth in 2022 to move to the top of the global medtech ranking. The strength of the US dollar was not kind to companies reporting in local currencies.

Newer Therapy Areas Will Drive Women’s Health Funding In 2024

 
• By Marion Webb

Women’s health startups focusing on areas of high unmet need such as menopause, infertility, preventive care and post-partum care will continue to attract investors in 2024. Meanwhile, machine learning and AI, as well as next-generation treatments such as psychedelic therapy, stand to drive advancements in the space.

Macro Challenges Make Calls On Newly Resilient Medtechs

 
• By Ashley Yeo

Global medtechs had a big enough challenge with COVID-19 and its aftermath before the full-scale regional conflict in Ukraine added more uncertainty to the question of when market normality would return.

MTI 100 Company Rankings

Medtech Insight’s MTI 100 comprises a set of industry league tables providing US dollar rankings of medtech companies according to their overall annual medical device and IVD revenues, where appropriate and product sector-specific revenues where possible.

The 2022 MTI 100 list includes a new intake of rapidly growing companies, with the result that the threshold for inclusion has risen to over $400m. Many companies in the lower reaches of previous years’ rankings have fallen below the threshold.

The leading companies are those familiar faces that have long shaped the structure of the medtech industry and driven its growth. More than usual swapping of places is evident among the Top 12, as a result of past M&A, portfolio reshaping, strategic management interventions and the waning significance of COVID-associated revenues in 2022.

Figures shown are for the year ended 31 December 2022, except where noted, while most Japanese companies’ 31 March 2023 year-ends are reflected.

The data below is as of 22 November 2023. Unless noted, the tables show reported external medtech-specific sales values of publicly owned companies at manufacturer level and exclude service revenues unless noted. Average annual exchange US dollar exchange rates from 31 December 2022 are used for comparative purposes, regardless of the company’s financial year end (for the major currencies: $1.054 to the Euro; $0.0076 to the Yen; $1.048 to the Swiss Franc; $1.24 to the £)

For more information contact Ashley.Yeo@citeline.com